While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

A Novo Nordisk production line in Denmark for Ozempic pens. This could suggest anti-inflammatory benefits, or show that ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Novo Nordisk (NVO) ended a five-day losing streak ... rating on the maker of hugely popular obesity/ diabetes drugs, Ozempic and Wegovy. Nine years after starting its coverage, the Paris-based ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s Wegovy and ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...

the active ingredient of Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief executive said on Friday. The patent protection for semaglutide ...